Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma

被引：0
|
作者：
Jeeyun Lee
Joon Oh Park
Won Seog Kim
Se Hoon Park
Keon Woo Park
Moon Seok Choi
Joon Hyoek Lee
Kwang Cheol Koh
Seung Woon Paik
Byung Chul Yoo
Jaewon Joh
Kihyun Kim
Chul Won Jung
Young Suk Park
Young-Hyuck Im
Won Ki Kang
Mark H. Lee
Keunchil Park
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center
[2] Sungkyunkwan University School of Medicine,Division of Gastroenterology, Department of Medicine, Samsung Medical Center
[3] Sungkyunkwan University School of Medicine,Department of Surgery, Samsung Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2004年 / 54卷
关键词：
Doxorubicin; Cisplatin; Hepatocellular carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：385 / 390
页数：5
相关论文
共 50 条
  • [21] A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma
    Ji Eun Uhm
    Joon Oh Park
    Jeeyun Lee
    Young Suk Park
    Se Hoon Park
    Byung Chul Yoo
    Seung Woon Paik
    Kwang Cheol Koh
    Won Ki Kang
    Ho Yeong Lim
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 929 - 935
  • [22] A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma
    Halm, U
    Etzrodt, G
    Schiefke, I
    Schmidt, F
    Witzigmann, H
    Mössner, J
    Berr, F
    ANNALS OF ONCOLOGY, 2000, 11 (01) : 113 - 114
  • [23] A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma
    Zhu, AX
    Fuchs, CS
    Clark, JW
    Muzikansky, A
    Taylor, K
    Sheehan, S
    Tam, K
    Yung, E
    Kulke, MH
    Ryan, DP
    ONCOLOGIST, 2005, 10 (06) : 392 - 398
  • [24] A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma
    Ruff, P
    Chasen, MR
    Long, JEH
    van Rensburg, CEJ
    ANNALS OF ONCOLOGY, 1998, 9 (02) : 217 - 219
  • [25] A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma
    McCarthy, JS
    Tannock, IF
    Degendorfer, P
    Panzarella, T
    Furlan, M
    Siu, LL
    ORAL ONCOLOGY, 2002, 38 (07) : 686 - 690
  • [26] A PHASE-II TRIAL OF RECOMBINANT LEUKOCYTE INTERFERON PLUS DOXORUBICIN IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA
    FEUN, LG
    SAVARAJ, N
    HUNG, SE
    REDDY, R
    JEFFERS, L
    BENEDETTO, P
    LIVINGSTONE, AS
    ARDALAN, B
    LEVI, JU
    PARKER, T
    SCHIFF, ER
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (05): : 393 - 395
  • [27] A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma
    Mok, TSK
    Leung, TWT
    Lee, SD
    Chao, Y
    Chan, ATC
    Huang, A
    Lui, MC
    Yeo, W
    Chak, K
    Johnston, A
    Johnson, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (04) : 307 - 311
  • [28] Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
    El Dika, Imane
    Capanu, Marinela
    Chou, Joanne F.
    Harding, James J.
    Ly, Michele
    Hrabovsky, Anna D.
    Do, Richard K. G.
    Shia, Jinru
    Millang, Brittanie
    Ma, Jennifer
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    CANCER MEDICINE, 2020, 9 (20): : 7453 - 7459
  • [29] A phase II study of cisplatin and vinorelbine in patients with metastatic breast cancer
    Mustacchi, G
    Muggia, M
    Milani, S
    Ceccherini, R
    Leita, ML
    Dellach, C
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1730 - 1736
  • [30] Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma
    Chia, Whay Kuang
    Ong, Simon
    Toh, Han Chong
    Hee, Siew Wan
    Choo, Su Pin
    Poon, Donald Y. H.
    Tay, Miah Hiang
    Tan, Chee Kiat
    Koo, Wen Hsin
    Foo, Kian Fong
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2008, 37 (07) : 554 - 558
12345